Müller Lena, Aigner Petra, Stoiber Dagmar
Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria.
Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.
Front Immunol. 2017 Mar 31;8:304. doi: 10.3389/fimmu.2017.00304. eCollection 2017.
Type I interferons (IFNs) are known to mediate antitumor effects against several tumor types and have therefore been commonly used in clinical anticancer treatment. However, how IFN signaling exerts its beneficial effects is only partially understood. The clinically relevant activity of type I IFNs has been mainly attributed to their role in tumor immune surveillance. Different mechanisms have been postulated to explain how type I IFNs stimulate the immune system. On the one hand, they modulate innate immune cell subsets such as natural killer (NK) cells. On the other hand, type I IFNs also influence adaptive immune responses. Here, we review evidence for the impact of type I IFNs on immune surveillance against cancer and highlight the role of NK cells therein.
已知I型干扰素（IFN）可介导针对多种肿瘤类型的抗肿瘤作用，因此已普遍用于临床抗癌治疗。然而，IFN信号传导如何发挥其有益作用仅得到部分理解。I型干扰素的临床相关活性主要归因于它们在肿瘤免疫监视中的作用。已经提出了不同的机制来解释I型干扰素如何刺激免疫系统。一方面，它们调节天然免疫细胞亚群，如自然杀伤（NK）细胞。另一方面，I型干扰素也影响适应性免疫反应。在此，我们综述了I型干扰素对癌症免疫监视影响的证据，并强调了NK细胞在其中的作用。
